J&J's Spra­va­to pulls a PhI­II win against Sero­quel XR in treat­ment-re­sis­tant de­pres­sion

A day be­fore Thanks­giv­ing, J&J’s Janssen has a new cut of Phase III Spra­va­to da­ta to be grate­ful for.

The phar­ma gi­ant an­nounced on Wednes­day that its nasal spray, al­so known as es­ke­t­a­mine, beat ex­tend­ed-re­lease que­ti­ap­ine, pre­vi­ous­ly sold by As­traZeneca as Sero­quel XR, in treat­ment-re­sis­tant de­pres­sion (TRD). Of 676 adults, a sig­nif­i­cant­ly high­er num­ber of pa­tients on Spra­va­to were able to achieve re­mis­sion and avoid re­lapse af­ter 32 weeks, ac­cord­ing to J&J.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA